cliffwatch

dalbavancin hydrochloride · Abbvie · NDA 021883

Dalvance

Earliest generic entry, as listed
23 May 2028

Blocked by patent: US 6900175. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 1 unexpired

PatentClaimsExpires
US 6900175use U-349923 May 2028

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026First generic approved · 021883-001
  • 25 Oct 2026Generic approved · 021883-001
  • 25 Oct 2026Generic approved · 021883-001
  • 25 Oct 2026Generic approved · 021883-001
  • 25 Oct 2026Generic approved · 021883-001
  • 25 Oct 2026Generic approved · 021883-001

Products covered · 1

NDA · productFormStrengthListed expiry
021883 · 001 · RLDpowder, intravenousEQ 500MG BASE/VIAL23 May 2028